vir-5525
vir-5525: developed by 1 company · 1 clinical trial tracked.
vir-5525 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect vir-5525 to VIR; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could vir-5525 → VIR affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Solid Tumor Malignancies
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Vir Biotechnology, Inc. (VIR) Solid Tumor Malignancies | Phase 1 |
Clinical Trials (1)
A Phase 1, First-in-Human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5525 Alone and in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Primary endpoint: Primary Safety Objectives (Parts 1 and 3)
Interventionalopen450 targetStarted 2025-07Completion 2029-084 sites · Australia, United StatesVir Biotechnology, Inc.
Frequently asked questions
Who is developing vir-5525?
vir-5525 is being developed by Vir Biotechnology, Inc..
How many clinical trials involve vir-5525?
BioSniper tracks 1 clinical trial involving vir-5525.